Clinic
Legacy Meridian Park Hospital
Legacy Meridian Park Hospital was paid $13.28M by Medicaid between Jan 2018 and Nov 2024, across 47 billing codes. Its largest line is 99285, emergency room visit (most serious) — 35% of everything it billed.
33Billing provider infoLEGACY MERIDIAN PARK HOSPITAL
TUALATIN, OR 97062
TUALATIN, OR 97062
33aNPI1184647620assigned 07/25/2006
33bProvider typeClinic/Center
28Total paid$13.28M
24GClaims140,544
24DCodes billed47
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinic/Center providers in Oregon
Rank by total paid#4 of 167
Median peer was paid$141K
This provider vs. median94×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official JENSEN, SARAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,884 | $1.20M | |
| 2019 | 16,457 | $1.51M | |
| 2020 | 13,371 | $1.37M | |
| 2021 | 19,725 | $1.91M | |
| 2022 | 26,796 | $2.32M | |
| 2023 | 25,315 | $2.53M | |
| 2024incomplete | 22,996 | $2.44M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 35% | 14,502 | 13,110 | $4.59M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 17,717 | 16,358 | $4.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 16,194 | 14,762 | $2.76M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.8% | 8,650 | 7,889 | $1.04M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 1,514 | 1,260 | $157K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 3,697 | 3,352 | $149K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 932 | 881 | $84K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 626 | 593 | $53K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 157 | 151 | $36K |
| 71045 | Radiologic examination, chest; single view | <1% | 634 | 554 | $27K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 250 | 198 | $21K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 397 | 363 | $14K |
35 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 442 | $12K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 69 | $7K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,345 | $6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 100 | $5K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,656 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 28 | $3K |
| 80053 | Comprehensive metabolic panel | <1% | 15,627 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 26,623 | $2K |
| 87631 | <1% | 378 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 100 | $1K |
| 71271 | <1% | 13 | $880.07 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 932 | $704.67 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,482 | $292.97 |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,074 | $143.25 |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $142.88 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 112 | $135.00 |
| 84703 | <1% | 1,799 | $128.73 | |
| 83690 | <1% | 2,255 | $74.57 | |
| 84484 | <1% | 2,411 | $65.32 | |
| 81003 | <1% | 2,942 | $45.25 | |
| 83735 | <1% | 404 | $6.03 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 2,391 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 13 | $0.00 |
| 36592 | 0% | 13 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 1,025 | $0.00 |
| 81001 | 0% | 162 | $0.00 | |
| 82077 | 0% | 305 | $0.00 | |
| 85027 | 0% | 280 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 52 | $0.00 |
| 96376 | 0% | 12 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 47 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 43 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 78 | $0.00 |
| A9270 | Non-covered item or service | 0% | 18 | $0.00 |
| 87430 | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJENSEN, SARAH (VP FINANCE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.